Regeneron Pharmaceuticals (REGN) Change in Cash (2009 - 2026)

Regeneron Pharmaceuticals' Change in Cash history runs 18 years deep, the most recent figure standing at -$153.1 million for Q1 2026.

• In Q1 2026, Change in Cash fell 125.35% year-over-year to -$153.1 million; the TTM figure through Mar 2026 stood at -$122.4 million (down 125.33% YoY), while the FY2025 annual figure was $634.7 million, up 355.1% from the prior year.
• Change in Cash was -$153.1 million for Q1 2026 at Regeneron Pharmaceuticals, down from $610.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $809.4 million in Q1 2023 to a low of -$2.0 billion in Q2 2023.
• Historically, Change in Cash has averaged $4.3 million across 5 years, with a median of $96.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Cash sank 4106.28% in 2023, then surged 571.88% in 2025.
• A 5-year view of Change in Cash shows it stood at -$385.4 million in 2022, then jumped by 249.87% to $577.6 million in 2023, then declined by 17.38% to $477.2 million in 2024, then gained by 27.95% to $610.6 million in 2025, then slumped by 125.07% to -$153.1 million in 2026.
• The last three Change in Cash figures came in at -$153.1 million (Q1 2026), $610.6 million (Q4 2025), and $497.5 million (Q3 2025), per Business Quant data.